Skip to main content
Erschienen in: Digestive Diseases and Sciences 2/2007

01.02.2007 | Original Article

Predictors and Noninvasive Identification of Severe Liver Fibrosis in Patients with Chronic Hepatitis C

verfasst von: Mohamed A. Metwally, Claudia O. Zein, Nizar N. Zein

Erschienen in: Digestive Diseases and Sciences | Ausgabe 2/2007

Einloggen, um Zugang zu erhalten

Abstract

Diagnosis of severe fibrosis (stages III and IV) in hepatitis C has clinical implications. Our objective was to distinguish independent predictors of severe fibrosis and use them to identify patients with severe fibrosis without a liver biopsy. One hundred ninety-nine hepatitis C patients were included in the initial analysis to identify predictors of severe fibrosis. Univariate and multivariate analyses of 26 predetermined variables for significance in predicting severe fibrosis were performed. Based on the coefficient regression and P values, a scoring system was developed and applied to a second independent cohort (137 patients) for validation. In multivariate analysis, low platelet count, low albumin, aspartate transaminase level, history of blood transfusion, and hepatitis B core antibody were significant independent predictors of severe fibrosis. A scoring system (range, 0–9) was developed from the three variables with the lowest P values (platelet count, aspartate transaminase, and albumin). A cutoff point of 4 had 99% specificity and 94% positive predictive value. A cutoff point of 2 had 87% sensitivity and 95% negative predictive value. We conclude that severe fibrosis in hepatitis C may potentially be identified with a high degree of certainty in a substantial number of patients with a simple noninvasive scoring system.
Literatur
1.
Zurück zum Zitat WHO/Viral Hepatitis Prevention Board (1999) Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat 6:35–47CrossRef WHO/Viral Hepatitis Prevention Board (1999) Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat 6:35–47CrossRef
2.
Zurück zum Zitat Alter MJ, Kruszon-Moran D, Nainan OV, et al. (1999) The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 341:556–562PubMedCrossRef Alter MJ, Kruszon-Moran D, Nainan OV, et al. (1999) The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 341:556–562PubMedCrossRef
3.
Zurück zum Zitat Alter MJ (1995) Epidemiology of hepatitis C in the West. Semin Liver Dis 15:5–14PubMed Alter MJ (1995) Epidemiology of hepatitis C in the West. Semin Liver Dis 15:5–14PubMed
4.
Zurück zum Zitat Terrault N, Wright T (1995) Interferon and hepatitis C virus infection. N Engl J Med 332:1509–1511PubMedCrossRef Terrault N, Wright T (1995) Interferon and hepatitis C virus infection. N Engl J Med 332:1509–1511PubMedCrossRef
5.
Zurück zum Zitat Di Bisceglie AM (2000) Natural history of hepatitis C: its impact on clinical management. Hepatology 31:1014–1018PubMedCrossRef Di Bisceglie AM (2000) Natural history of hepatitis C: its impact on clinical management. Hepatology 31:1014–1018PubMedCrossRef
6.
Zurück zum Zitat Kiyosawa K, Sodeyama T, Tanaka E, et al. (1990) Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology 12:671–675PubMed Kiyosawa K, Sodeyama T, Tanaka E, et al. (1990) Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology 12:671–675PubMed
7.
Zurück zum Zitat Poynard T, McHutchison J, Goodman Z, Ling MH, Albrecht J (2000) Is an “a la carte” combination interferon alfa-2b plus ribavirinregimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group. Hepatology 31:211–218PubMedCrossRef Poynard T, McHutchison J, Goodman Z, Ling MH, Albrecht J (2000) Is an “a la carte” combination interferon alfa-2b plus ribavirinregimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group. Hepatology 31:211–218PubMedCrossRef
8.
Zurück zum Zitat Khan MH, Thomas L, Byth K, et al. (1998) How much does alcohol contribute to the variability of hepatic fibrosis in chronic hepatitis C? J Gastroenterol Hepatol 13:419–426PubMed Khan MH, Thomas L, Byth K, et al. (1998) How much does alcohol contribute to the variability of hepatic fibrosis in chronic hepatitis C? J Gastroenterol Hepatol 13:419–426PubMed
9.
Zurück zum Zitat Hourigan LF, Macdonald GA, Purdie D, et al. (1999) Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology 29:1215–1219PubMedCrossRef Hourigan LF, Macdonald GA, Purdie D, et al. (1999) Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology 29:1215–1219PubMedCrossRef
10.
Zurück zum Zitat Bonacini M, Hadi G, Govindarajan S, Lindsay KL (1997) Utility of a discriminant score for diagnosing advanced fibrosis or cirrhosis in patients with chronic hepatitis C virus infection. Am J Gastroenterol 92:1302–1304PubMed Bonacini M, Hadi G, Govindarajan S, Lindsay KL (1997) Utility of a discriminant score for diagnosing advanced fibrosis or cirrhosis in patients with chronic hepatitis C virus infection. Am J Gastroenterol 92:1302–1304PubMed
11.
Zurück zum Zitat Saadeh S, Cammell G, Carey WD, Younossi Z, Barnes D, Easley K (2001) The role of liver biopsy in chronic hepatitis C. Hepatology 33:196–200PubMedCrossRef Saadeh S, Cammell G, Carey WD, Younossi Z, Barnes D, Easley K (2001) The role of liver biopsy in chronic hepatitis C. Hepatology 33:196–200PubMedCrossRef
12.
Zurück zum Zitat Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T, MULTIVIRC Group (2001) Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 357:1069–1075PubMedCrossRef Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T, MULTIVIRC Group (2001) Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 357:1069–1075PubMedCrossRef
13.
Zurück zum Zitat Wannamethee G, Shaper AG (1988) Men who do not drink: a report from the British Regional Heart Study. Int J Epidemiol 17:307–316PubMedCrossRef Wannamethee G, Shaper AG (1988) Men who do not drink: a report from the British Regional Heart Study. Int J Epidemiol 17:307–316PubMedCrossRef
14.
Zurück zum Zitat Zein NN, Rakela J, Krawitt EL, Reddy KR, Tominaga T, Persing DH (1996) Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity, and response to interferon therapy. Collaborative Study Group. Ann Intern Med 125:634–639PubMed Zein NN, Rakela J, Krawitt EL, Reddy KR, Tominaga T, Persing DH (1996) Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity, and response to interferon therapy. Collaborative Study Group. Ann Intern Med 125:634–639PubMed
15.
Zurück zum Zitat The French METAVIR Cooperative Study Group (1994) Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 20:15–20CrossRef The French METAVIR Cooperative Study Group (1994) Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 20:15–20CrossRef
16.
Zurück zum Zitat Bedossa P, Poynard T (1996) An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 24:289–293PubMedCrossRef Bedossa P, Poynard T (1996) An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 24:289–293PubMedCrossRef
17.
Zurück zum Zitat Hanley JA, McNeil BJ (1982) The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 143:29–36PubMed Hanley JA, McNeil BJ (1982) The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 143:29–36PubMed
18.
Zurück zum Zitat Kamath PS, Wiesner RH, Malinchoc M, et al. (2001) A model to predict survival in patients with end-stage liver disease. Hepatology 33:464–470PubMedCrossRef Kamath PS, Wiesner RH, Malinchoc M, et al. (2001) A model to predict survival in patients with end-stage liver disease. Hepatology 33:464–470PubMedCrossRef
19.
Zurück zum Zitat Lechner K, Niessner H, Thaler E (1977) Coagulation abnormalities in liver disease. Semin Thromb Hemost 4:40–56PubMed Lechner K, Niessner H, Thaler E (1977) Coagulation abnormalities in liver disease. Semin Thromb Hemost 4:40–56PubMed
20.
Zurück zum Zitat Aoki Y, Hirai K, Tanikawa K (1993) Mechanism of thrombocytopenia in liver cirrhosis: kinetics of indium-111 tropolone labelled platelets. Eur J Nucl Med 20:123–129PubMedCrossRef Aoki Y, Hirai K, Tanikawa K (1993) Mechanism of thrombocytopenia in liver cirrhosis: kinetics of indium-111 tropolone labelled platelets. Eur J Nucl Med 20:123–129PubMedCrossRef
21.
Zurück zum Zitat de Noronha R, Taylor BA, Wild G, Triger DR, Greaves M (1991) Inter-relationships between platelet count, platelet IgG, serum IgG, immune complexes and severity of liver disease. Clin Lab Haematol 13:127–135PubMedCrossRef de Noronha R, Taylor BA, Wild G, Triger DR, Greaves M (1991) Inter-relationships between platelet count, platelet IgG, serum IgG, immune complexes and severity of liver disease. Clin Lab Haematol 13:127–135PubMedCrossRef
22.
Zurück zum Zitat Sheth SG, Flamm SL, Gordon FD, Chopra S (1998) AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection. Am J Gastroenterol 93:44–48PubMedCrossRef Sheth SG, Flamm SL, Gordon FD, Chopra S (1998) AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection. Am J Gastroenterol 93:44–48PubMedCrossRef
23.
Zurück zum Zitat De Maria N, Colantoni A, Friedlander L, et al. (2000) The impact of previous HBV infection on the course of chronic hepatitis C. Am J Gastroenterol 95:3529–3536PubMedCrossRef De Maria N, Colantoni A, Friedlander L, et al. (2000) The impact of previous HBV infection on the course of chronic hepatitis C. Am J Gastroenterol 95:3529–3536PubMedCrossRef
24.
Zurück zum Zitat Gordon SC, Elloway RS, Long JC, Dmuchowski CF (1993) The pathology of hepatitis C as a function of mode of transmission: blood transfusion vs. intravenous drug use. Hepatology 18:1338–1343PubMedCrossRef Gordon SC, Elloway RS, Long JC, Dmuchowski CF (1993) The pathology of hepatitis C as a function of mode of transmission: blood transfusion vs. intravenous drug use. Hepatology 18:1338–1343PubMedCrossRef
Metadaten
Titel
Predictors and Noninvasive Identification of Severe Liver Fibrosis in Patients with Chronic Hepatitis C
verfasst von
Mohamed A. Metwally
Claudia O. Zein
Nizar N. Zein
Publikationsdatum
01.02.2007
Erschienen in
Digestive Diseases and Sciences / Ausgabe 2/2007
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-006-9366-z

Weitere Artikel der Ausgabe 2/2007

Digestive Diseases and Sciences 2/2007 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

28.05.2024 NSCLC Nachrichten

Eine perioperative Therapie mit Nivolumab reduziert das Risiko für Rezidive und Todesfälle bei operablem NSCLC im Vergleich zu einer alleinigen neoadjuvanten Chemotherapie um über 40%. Darauf deuten die Resultate der Phase-3-Studie CheckMate 77T.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.